Antifungal drugs for specialist use only (Formulary)

TAM (Treatments and Medicines) NHS Highland
NHS Highland

Use only in accordance with protocols or on advice of Microbiology, Infectious Diseases or appropriate Consultant Specialist.

AMPHOTERICIN B

Therapy notes

MHRA advice: Liposomal and lipid-complex formulations: name change to reduce medication errors (July 2020) (www.gov.uk).
MHRA advice: Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused (July 2018) (www.gov.uk).

Formulation and dosage details

Formulation:

Infusion 50mg (Fungizone®) (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Formulation and dosage details

Formulation:

Powder for dispersion for infusion 50mg (AmBisome Liposomal®) (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

ANIDULAFUNGIN

Therapy notes

Formulation and dosage details

Formulation:

Infusion 100mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

CASPOFUNGIN

Therapy notes

Formulation and dosage details

Formulation:

Infusion 50mg, 70mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

FLUCYTOSINE

Therapy notes

MHRA alert: Flucytosine (Ancotil): new contraindication in patients with DPD deficiency (October 2020) (www.gov.uk).

Formulation and dosage details

Formulation:

Infusion 2·5 grams/250mL (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

POSACONAZOLE

Therapy notes

MHRA advice: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable (September 2016) (www.gov.uk).

  • Use tablets in preference to the oral suspension. 
  • Due to differences in the dosing of each formulation the tablets and oral suspension are not interchangeable.

Formulation and dosage details

Formulation:

Tablets 100mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Formulation and dosage details

Formulation:

Oral suspension 200mg/5mL (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

VORICONAZOLE

Therapy notes

MHRA advice: Voriconazole: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma (December 2014) (www.gov.uk).

Risk minimisation materials

Formulation and dosage details

Formulation:

Tablets 50mg, 200mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Formulation and dosage details

Formulation:

Oral suspension 200mg/5mL (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Formulation and dosage details

Formulation:

Intravenous infusion 200mg (Protected antibiotic to be prescribed on the advice of an infection specialist only) 

Editorial Information

Document Id: F275